Get the Stockscreener App
6.18
0.40%
-0.025
After Hours:
6.18
Uniqure N V stock is traded at $6.18, with a volume of 851.55K.
It is down -0.40% in the last 24 hours and down -3.74% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$6.205
Open:
$6.26
24h Volume:
851.55K
Relative Volume:
1.30
Market Cap:
$295.87M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-1.5685
EPS:
-3.94
Net Cash Flow:
$-153.08M
1W Performance:
-19.32%
1M Performance:
-3.74%
6M Performance:
+23.35%
1Y Performance:
-10.30%
1-Day Range:
$5.87
$6.31
1-Week Range:
$5.87
$7.505
52-Week Range:
$3.73
$11.35
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| QURE | 6.18 | 295.87M | 15.84M | -308.48M | -153.08M | -3.94 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure NV (LTS:0EE0) Enterprise Value : $-65.19 Mil (As of Nov. 16, 2024) - GuruFocus.com
uniQure FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Privium Fund Management B.V. Acquires 104,500 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade - Yahoo Finance
(QURE) On The My Stocks Page - Stock Traders Daily
uniQure FY2024 EPS Estimate Boosted by Leerink Partnrs - MarketBeat
HC Wainwright Issues Positive Estimate for uniQure Earnings - MarketBeat
William Blair Issues Positive Estimate for uniQure Earnings - MarketBeat
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - cnhinews.com
What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates - Yahoo Finance
QUREuniQure N.V. Latest Stock News & Market Updates - StockTitan
Cantor Fitzgerald Reaffirms "Overweight" Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
uniQure N.V. Reports Q3 2024 Progress and Financials - TipRanks
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Uniqure NV earnings beat by $0.11, revenue fell short of estimates - Investing.com Australia
UniQure: Q3 Earnings Snapshot - San Francisco Chronicle
uniQure NV Q3 2024 Earnings: EPS Loss of $0.91 Beats Estimates, Revenue of $2.3 Million Misses Expectations - GuruFocus.com
uniQure reports Q3 EPS (91c), consensus ($1.01) - TipRanks
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
uniQure's Breakthrough: Huntington's Trial Success, $435M Cash Runway Through 2027 | QURE Stock News - StockTitan
abrdn plc Buys 1,528,581 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Assenagon Asset Management S.A. Has $1.34 Million Stake in uniQure (NASDAQ:QURE) - MarketBeat
Multiple Insiders Sold uniQure Shares Presenting Weak Signs For Investors - Simply Wall St
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
(QURE) Investment Analysis - Stock Traders Daily
uniQure (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Pfizer Loses Hemophilia Gene Therapy Patent Row To UniQure - Law360
uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring - Seeking Alpha
State Street Corp's Strategic Reduction in uniQure NV Holdings - GuruFocus.com
How To Trade (QURE) - Stock Traders Daily
uniQure (NASDAQ:QURE) Upgraded to Sell by StockNews.com - MarketBeat
uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell” - Defense World
uniQure N.V. (QURE) requires closer examination - US Post News
uniQure Initiates Trial for Promising ALS Gene Therapy - TipRanks
uniQure announces dosing of first patient in Phase I/II trial of AMT-162 - TipRanks
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - StockTitan
Raymond James gives an Outperform recommendation for uniQure N.V. (QURE) - Knox Daily
Ratios Uncovered: Breaking Down uniQure N.V. (QURE)’s Trailing Twelve Months Metrics - The Dwinnex
Marshall Wace LLP Invests $175,000 in uniQure (NASDAQ:QURE) - Defense World
uniQure shares coverage resumed on robust clinical portfolio - Investing.com
Raymond James Reiterates Outperform Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure shares coverage resumed on robust clinical portfolio By Investing.com - Investing.com UK
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
An analyst sees good growth prospects for uniQure N.V. (QURE) - SETE News
Market Recap: uniQure N.V. (QURE)’s Positive Momentum, Closing at 5.92 - The Dwinnex
The uniQure N.V. (QURE) had a good session last reading, didn’t it? - US Post News
uniQure N.V.’s Mixed Bag: Up 9.71% in 6 Months, Up 2.17% in 30 Days - The InvestChronicle
uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 10% this week, taking five-year losses to 89% - Simply Wall St
Technical analysis of uniQure N.V. (QURE) stock chart patterns - US Post News
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):